Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FFBL0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $146,420
Award facts
- Contract value 100% obligated
- $146,420.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $146,420.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. This firm fixed-price delivery order, issued on November 13, 2025, with an ultimate completion date of November 14, 2025, represents a purchase from DMS Pharmaceutical Group's larger Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The PPV-G GEN V is a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors capable of supplying a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the defense pharmaceutical supply chain, holding a single-award IDC under the PPV-G GEN V contract (SPE2DR) with a ceiling value of $499,999,999 and completion date of December 31, 2036. The company, registered in the System for Award Management since 2001, has no identified subcontractors and competed this award without a set-aside designation, reflecting its competitive capability in unrestricted federal procurement. This delivery order exemplifies the company's established performance in fulfilling the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBL0?
SPE2DR26FFBL0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FFBL0 worth?
The government has obligated $146,420 on SPE2DR26FFBL0.
Is contract SPE2DR26FFBL0 an order under another contract?
Yes. SPE2DR26FFBL0 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBL0 competed?
The extent of competition for SPE2DR26FFBL0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award